bluuebunny/crossref_metadata_2025 huggingface dataset:
0510 The Apnea and Insomnia Research (AIR) Trial: A Preliminary Report
Authors: Edinger J D , Manber R
Published: May 2020

Introduction

Many sleep apnea patients suffer from comorbid insomnia disorder. Although cognitive behavioral insomnia therapy (CBTI) is recommended as the first line insomnia treatment for such patients, access to trained providers of this treatment remains limited. The current study is testing he efficacy of an online CBTI among CPAP treated sleep apnea patient with comorbid insomnia.

Methods

Patients enrolled in this trial complete baseline measures and then are randomized to either an online version of Cognitive Behavioral Insomnia Therapy (CBTI) or no additional treatment beyond their CPAP therapy (CTRL). After 8 weeks of treatment all patients are reassessed. The current report considers changes in scores on the ISI and Epworth Sleepiness Scale (ESS) as well as average minutes of nightly CPAP use from pre-treatment to the end of the initial 8 weeks of online treatment relative to the no treatment CTRL. The sample for this report included the first 170 participants enrolled in this trial (mean age = 56.5±12.5 yrs; 60.1% females).

Results

Those receiving online CBTI showed greater reductions in their ISI scores from baseline to the end of the initial 8-week treatment phase than did those in the CTRL group (p = .0009). Average ISI score improvements among those receiving online CBTI moved patients from moderately severe insomnia to mild insomnia symptoms. In contrast, no differences were noted between the online CBTI and CTRL groups in regard to pre- to post-treatments changes on the ESS (p= .3771) scores or amount of CPAP use (p = .8053).

Conclusion

Whereas online CBTI does not seem to reduce daytime sleepiness or improve CPAP adherence among patients with comorbid sleep apnea and insomnia, it appears to be an effective intervention for reducing insomnia severity for this patient group.

Support

National Heart. Lung and Blood Institute Grant # 1R01HL130559-01A1
0525 Subtypes of Efficacy of Cognitive-Behavioral Therapy for Insomnia
Authors: Castronovo V , Sforza M , Galbiati A , Salsone M , Marelli S , Ferini-Strambi L
Published: May 2020

Introduction

Cognitive-Behavioral Therapy for Insomnia (CBT-I) is the ﬁrst-line treatment for Insomnia disorder (ID). We aimed to identify ID patients’ subtypes based on clinical features and their response to CBT-I.

Methods

294 chronic insomnia patients (61.6% female, mean age 40.7 ± 12.3 yrs) underwent 7-sessions group CBT-I. By use of latent class analysis (LCA) we identified insomnia disorder subtypes according to baseline (BL) evaluation of non-sleep indices and the response to CBT-I (Delta score of Insomnia Severity Index ISI between BL and end-of-treatment (ET). Moreover, we assessed ISI in 123 out of 294 insomnia patients (82 females (66.7%), mean age 40.59 ± 11.89 years) who completed a follow-up evaluation (FU) within a range of 4-10 years.

Results

We chose 3 latent classes as most parsimonious model. We identified Class 1 (insomnia+anxiety+depression+stress) (n=62), Class 2 (insomnia+anxiety+depression) (n=153) and Class 3 (only-insomnia) (n=79). The effect of CBT-I was maintained up to 10 years after the ET in the three classes but with significant difference between classes (p<0.05). At the ET, the largest percentage of responders (ISI decrease ≥ 8) was found in Class 1 (63.5%). Results of overall CBT-I effectiveness: in Class 3, 98.6% had subthreshold insomnia (ISI score=0-14) at the ET, and 97.2% at the FU; in Class 2, 89.0% at the ET, and 78.2% at the FU; in Class 1, 80.7% at ET and 51.8% at the FU.

Conclusion

Our analysis identified three different subtypes of insomniacs on the basis of clinical outcomes. The presence of anxiety and depression did not diminish the effect of CBT-I both short and long term. However, ID patients characterized by the presence of stress (Class 1) were the best responders at the ET but this was not maintained at the FU evaluation. We can speculate that stress could be considered a risk factor that plays an important role in the long-term outcome of CBT-I.

Support

No
0527 The Uptake of a Free Digital CBTi Programme in a Large Commercial Organisation
Authors: Gardiner A , Stanley N
Published: May 2020

Introduction

CBTi is effective in the treatment of insomnia and is now recommended as the first-line treatment. However, despite the desirability of CBTi, access to therapy is restricted due to the lack of sufficient appropriately trained and experienced therapists. Because of the lack of therapists and the financial and time costs associated with face to face therapy a number of programmes that offer CBTi digitally have been developed, which have been shown to have similar success rates to receiving therapy in person.

Methods

The uptake of Sleepstation www.sleepstation.org.uk, a clinically proven CBTi platform with additional human support, was investigated when it was offered free to the members of a large organisation in the UK. The availability of the programme was promoted via the organisation’s website for 3 months.

Results

1173 people registered an interest in the programme of which 880 were assessed for suitability (73% female, median age 45yrs). 411 where offered treatment due to symptoms indicative of insomnia. 188 initiated treatment. 137 complete the programme or reached recovery. 112 showed an improvement in their sleep.

Conclusion

Simply reporting the success rate of CBTi only tells part of the story. Simply improving access to CBTi, whether face to face or digitally, does not necessarily improve the initiation, retention, and completion of CBTi therapy. Further research is needed to fully understand the real and perceived barriers to the use of CBTi.

Support

This study was facilitated by Sleepstation
0539 Are Short Sleepers Uncoupled Sleepers?
Authors: Hartescu I , Morgan K , Stensel D J , Thackray A E , King J A
Published: May 2020

Introduction

While short sleep durations (<7h/night) are associated with increased diabetes risk, there is limited evidence that increasing the habitual sleep duration of short sleepers is either feasible, or will reliably improve metabolic health outcomes. Furthermore, in the absence of insomnia disorder, it remains unclear whether habitual short sleep mainly reflects a genetic predisposition or a lifestyle choice. In a randomized controlled study we delivered a sleep extension protocol based on CBTi principles to overweight ‘short sleepers’ at increased risk of Type II diabetes.

Methods

18 male short sleepers (Mage=41.4; MBMI=29.57; baseline mean TST=5.8 h/ night) with no complaints of insomnia were randomized to the sleep extension intervention or control condition (printed sleep hygiene advice). The 6-week intervention commenced with personalized sleep re-scheduling negotiated in a 60-minute 1-to-1 session, and supported by elements of sleep hygiene, stimulus control, relaxation and cognitive strategies. Outcomes included sleep duration (actigraphy), fasting insulin, Mean Amplitude of Glycemic Excursions (MAGE) from continuous glucose monitoring, and blood pressure. Data were analyzed in linear fixed effects models including time, group and baselines values.

Results

Adherence to the 6-week protocol was high. Relative to controls (n=8), intervention participants (n = 10) showed a significant increase in TST (95%CI 46.91min, 101.64min, p<0.001; MDiff = 79.4min, p<0.001) and significant reductions in fasting insulin (95%CI -32.08 pmol/L, -.97.0 pmol/L; p=0.04; MDiff = -10.2 pmol/L, p=0.06); MAGE (95%CI -0.77, -0.08, p=0.02; MDiff -0.35, p=0.05) and diastolic (95%CI -22, -5, p=0.004; MDiff=-12, p=0.004); and systolic blood pressure (95%CI -20, -2, p=0.03; MDiff=-10, p=0.006).

Conclusion

CBTi-based sleep extension protocols offer feasible and effective lifestyle interventions in the management of metabolic health in overweight short sleepers who fit published categorization of non-complaining poor sleepers with an undeveloped insomnia identity whose subjective sleep experience and objective sleep characteristics are ‘uncoupled’.

Support

School of Sport, Exercise and Health Sciences, Loughborough University
0552 Investigating Pre-Sleep Processes and How They Influence Sleep: A Diary and Actigraphy Study
Authors: Maeder T , Whitford J , Feinaigle P , Karlen W , Seifritz E , Pace-Schott E F , Kleim B
Published: May 2020

Introduction

The current study examined the relationship between pre-sleep processes and sleep in the context of real-world stress exposure in medical students during an internship. Medical students are often exposed to a variety of stressors and potentially traumatic events and have been shown to be at risk to develop psychopathology. Previous research has shown an association between stress, psychological distress, and sleep disturbances. In this context, studies have investigated possible predictors for sleep disturbances. Recently, the period just prior to sleep onset has received increased interest. At the moment, little is known, however, about the influence of such pre-sleep processes. In this study, we investigated the influence of pre-sleep rumination and mindfulness on sleep disturbances.

Methods

In a prospective study, we examined a sample of 50 medical students from the University of Zurich. All participants completed their first medical internship over 9 months as part of medical school. Pre-sleep processes and sleep were indexed mid-internship using sleep diaries over seven consecutive days. Additionally, a Fitbit tracking device was used to objectively measure sleep. Correlational analyses and multilevel linear models were conducted.

Results

Results show associations between pre-sleep processes and sleep disturbances in this stress-exposed at-risk population. Multilevel mixed-effects models showed that over the period of 7 consecutive nights, pre-sleep rumination was a significant predictor of lower subjective sleep quality (B = -.085, SE = .036, p = .02), lower subjective total sleep time (B = -.124, SE = .043, p = .005), higher subjective sleep onset latency (B = 1.535, SE = .678, p = .025), and higher subjective wake-up frequency (B = .033, SE = .011, p = .003).

Conclusion

Together, our data suggest pre-sleep processes as potential targets for stress-prevention programs that could help reduce the negative influence of stress in at risk populations.

Support

NA
0559 Association of Rapid Eye Movement Sleep with Insulin Resistance in Han Chinese Patients With Obstructive Sleep Apnea
Authors: Zhang C , Xu H , Zou J , Guan J , Yi H , Yin S
Published: May 2020

Introduction

Obstructive sleep apnea (OSA) is increasingly associated with insulin resistance. The underlying pathophysiology remains unclear but rapid eye movement (REM) sleep has been hypothesized to play a key role. To investigate the associations of insulin resistance with respiratory events and sleep duration during REM sleep, 4,062 Han Chinese individuals with suspected OSA were screened and 2,899 were analyzed.

Methods

We screened 4,062 participants with suspected OSA who underwent polysomnography in our sleep center from 2009 to 2016. Polysomnographic variables, biochemical indicators, and physical measurements were collected. Logistic regression analyses were conducted to determine the odds ratios (ORs) and 95% confidence intervals (95% CIs) for insulin resistance as assessed by hyperinsulinemia, the homeostasis model assessment of insulin resistance (HOMA-IR), fasting insulin resistance index (FIRI), and Bennet’s insulin sensitivity index (ISI).

Results

The final analyses included 2,899 participants. After adjusting for age, gender, body mass index, waist circumference, mean arterial pressure, smoking status, alcohol consumption, and the apnea and hypopnea index during non-REM sleep (AHINREM), the results revealed that AHI during REM sleep (AHIREM) was independently associated with insulin resistance; across higher AHIREM quartiles, the ORs (95% CIs) for hyperinsulinemia were 1.340 (1.022, 1.757), 1.210 (0.882, 1.660), and 1.632 (1.103, 2.416); those for abnormal HOMA-IR were 1.287 (0.998, 1.661), 1.263 (0.933, 1.711), and 1.556 (1.056, 2.293); those for abnormal FIRI were 1.386 (1.048, 1.835), 1.317 (0.954, 1.818), and 1.888 (1.269, 2.807); and those for abnormal Bennet’s ISI were 1.297 (1.003, 1.678), 1.287 (0.949, 1.747), and 1.663 (1.127, 2.452) (P < 0.01 for all linear trends). Additionally, the results showed that for every 1-h increase in REM duration, the risk of hyperinsulinemia decreased by 22.3% (P < 0.05).

Conclusion

The present study demonstrated that AHIREM was independently associated with hyperinsulinemia and abnormal HOMA-IR, FIRI, and Bennet’s ISI. Additionally, REM sleep duration was independently associated with hyperinsulinemia.

Support

This study was supported by Grants-in-aid from Shanghai Municipal Commission of Science and Technology (No.18DZ2260200).
0561 Differences in Nasopharyngoscopic Airway Form Between Awake and Sleep, Sitting and Recumbent Position and Techniques
Authors: Nishimura Y , Hamed M
Published: May 2020

Introduction

To examine and compare the information derived from flexible fiber-optic nasopharyngoscopy in awake mimic snoring (AMS), Müller’s Maneuver (MM) and drug-induced sleep endoscopy (DISE), to determine if AMS and MM can be used in substitution for DISE as a streamlined method. We investigated their relation with the level and pattern of obstruction detected on AMS, MM and DISE.

Methods

This is a retrospective study of 15 obstructive sleep apnea patients with apnea hypopnea index from 8.3 to 105.2, ages 20 to 80 were included. Each patient underwent polysomnography and thorough a physical examination, including flexible nasopharyngoscopy with AMS, MM and DISE. Airway obstruction on these endoscopic procedures were described according to airway level and pattern of obstruction. They were classified 5 different types; Uvula type: anterior-posterior vibration of the uvula, no airway obstruction; L-R velum type: lateral (the left and right directions) airway narrowing at velum level, no airway obstruction; A-P velum type: anterior-posterior total airway obstruction at velum level; Tonsillar type: total airway obstruction at pharyngeal level; Circumferential type: circumferential total airway obstruction at velum level. AMS and MM were performed with patients in sitting and in recumbent position. DISE was performed only in recumbent position.

Results

In review of the three procedures, the results were much different. Airway was obstructed in all cases(100%, 15 of 15)in DISE, but not all cases in AMS and MM. When tonsillar type was seen in AMS, it was also seen in MM and DISE(100%, 5 of 5).

Conclusion

Flexible fiber-optic nasopharyngoscopy appears to be useful for evaluating airway obstruction. It might be not suitable to use AMS and MM in substitution for DISE(except tonsillar type). Muscle tonic relaxation of the upper airway between AMS, MM and DISE might be different (DISE>MM>AMS, recumbent>sitting).

Support
0568 Physiologic OSA Traits and CPAP Adherence Among Patients with Coronary Artery Disease and OSA
Authors: Zinchuk A , Yaggi H , Liang J , Chu J , Op De Beeck S , Stepnowski C , Wellman A , Peker Y , Sands S
Published: May 2020

Introduction

Obstructive sleep apnea (OSA) is common in patients with coronary artery disease (CAD), but adherence to continuous positive airway pressure (CPAP) in this population is poor. Low arousal threshold (ArTH), a pathophysiologic OSA trait, is associated with low rates of regular CPAP use in sleep clinic populations. We aimed to determine whether ArTH or other physiologic OSA traits (i.e. pharyngeal collapsibility, muscle compensation, loop gain) are associated with CPAP adherence in patients with CAD and OSA.

Methods

A secondary analysis of a randomized controlled trial of OSA treatment in patients with CAD (RICCADSA) was performed. OSA (apnea hypopnea index, AHI≥5/hour) was assessed by polysomnography. Arousal threshold (% eupneic ventilation, %Ve), loop gain (LG), pharyngeal collapsibility (%Ve) and compensation (%Ve) were estimated from polysomnography using a validated method. Adherence to auto-titrated CPAP (hours/night) was obtained from machine downloads at 1, 3, 6, 12 and 24 months. Mixed modelling was used to assess the association between OSA traits and CPAP adherence.

Results

Participants (n=262) were 64.1±7.9 years old, with BMI of 29.2±4.2 and 86% were men. The mean AHI was 40.8±23.6 events/hour with oxygen nadir of 81.3±7.1%. The median (IQR) CPAP adherence (hrs/night) was 3.0 (0.9, 5.8) at 1-mo and 3.0 (0.0, 5.6) at 24-mo. Compared to reference studies, the CAD patients exhibited an elevated LG 0.63 (0.53, 0.79), similar ArTH (%Ve) of 117.5% (106.5%, 136.4%), higher collapsibility (%Ve) at 90.1% (82.3%, 94.8%) and lower compensation (%Ve) at 3.7% (-0.7%, 8.7%).Only increasing pharyngeal muscle compensation was associated with lower CPAP adherence (β -0.04, p-value 0.048), effect modified by pharyngeal collapsibility (Compensation x Collapsibility, β <0.01, p-value 0.042).

Conclusion

In this group of patients with CAD, increasing muscle compensation was associated with lower CPAP adherence. Physiologic OSA traits may provide insight into prediction of CPAP adherence among patients with OSA and CAD.

Support

Zinchuk: Parker B. Francis Fellowship Program in Clinical Research. Sands: American Heart Association. Peker: Swedish Research Council, Swedish Heart-Lung Foundation.
0580 Habitual Sleep Pattern, Anxiety and Depression are Predictive of Excessive Daytime Sleepiness in a Large-Scale Clinical Samples of Obstructive Sleep Apnea
Authors: Chang S , Huang W , Liu Y , Lee P
Published: May 2020

Introduction

Excessive daytime sleepiness (EDS) is a common symptom that patients with obstructive sleep apnea (OSA) seek medical attention for. Prevalence ranged from 20% to 60%. Previous studies reported factors associated with EDS included age, body mass index (BMI), depression, and OSA severity. In most studies, the sample size was small, participants having specific co-morbidities, and the definitions of EDS was heterogeneous. Moreover, the association between anxiety, depression, habitual sleep pattern, and EDS has not been widely studied. Therefore, the present study aims to investigate the prevalence of EDS and associated factors, especially anxiety, depression, and habitual sleep pattern, in a large-scale clinical sample.

Methods

Data was prospectively collected from 8,081 adult patients who underwent initial overnight polysomnography (PSG) for the first time were referred from 2009 to 2016. Patients with total recording time less than 240 minutes and missing data were excluded. Data collected include demographics, anthropometrics, co-morbidities, and self-reported habitual sleep patterns. Subjective sleepiness was assessed by the Epworth Sleepiness Scale (ESS) with EDS defined as ESS ≥10. Anxiety and depression were assessed by the Hospital Anxiety and Depression Scale (HADS). The stepwise forward Logistic regression was used to identified predictors for EDS.

Results

In 5,780 (82.6%) patients with OSA (apnea-hypopnea index, AHI≥5/h), mean age was 63.9±0.2 yr, BMI was 27.7±0.1, and ESS was 10.4±0.1 and 80.5% were male. Prevalence of EDS in all OSA patients was 55.1% where the patients with severe OSA had higher prevalence (59.8%) than that in mild (49.5%) and moderate OSA (51.8%). Anxiety (OR: 2.036, 95% CI:1.153-1.502), depression (OR: 1.159, 95% CI:1.01-1.33), and short sleep (<6hr/night) (OR:1.316, 95% CI:1.32,1.70) were top three risk factors for EDS. Other risk factors for EDS included AHI, arousal index, % total sleep time with SpO2<90%, %REM, smoking while hypnotic use and long sleep (≥ 8hr/night) were associated with lower risk.

Conclusion

Anxiety, depression, short sleep are predictive and OSA severity are predictive of EDS while long sleep was associated with lower risk.

Support

National Taiwan University (NTU-EPR-104R8951-1; 105R8951-1; 106R880301), Center of electronics technology integration (NTU-107L900502, 108L900502) by the Ministry of Education in Taiwan and MediaTek Inc (201802034RIND).
0608 Concordance Between Current AASM And CMS Scoring Criteria for Obstructive Sleep Apnea in Hospitalized Persons with TBI: A NIDILRR and VA Model System Study
Authors: Richardson R , Dahdah M , Almeida E , Ricketti P , Silva M , Calero K , Magalang U , Scwhartz D
Published: May 2020

Introduction

The objective of this study was to compare OSA, demographic, and TBI characteristics across the American Academy of Sleep Medicine (AASM) and Centers for Medicare and Medicare (CMS) scoring rules in moderate to severe TBI undergoing inpatient neurorehabilitation.

Methods

This is a secondary analysis from a prospective clinical trial of sleep apnea at six TBI Model System study sites (n=248). Scoring was completed by a centralized center using both the AASM and CMS criteria for OSA. Hospitalization and injury characteristics were abstracted from the medical record and demographics obtained by interview by trained research assistants using TBI Model System standard procedures.

Results

OSA was prevalent using the AASM (66%) and CMS (41.5%) criteria with moderate to strong agreement (weighted kappa = 0.64 (95%CI = 0.58, 0.70). Significant differences were observed for participants meeting AASM and CMS criteria (Agreement Group; AG) compared to those meeting criteria for AASM but not CMS (Disagreement Group; DG). At AHI ≥ 5, the DG (n=61) had lower Emergency Department Glasgow Coma Scale Scores consistent with greater injury severity (median 5 vs. 13, p = 0.0050), younger age (median 38 vs 58, p<0.0001), and lower BMI (median 24.8 vs 22.1, p = 0.0007) compared to the AG (n=103). At AHI ≥ 15, female gender and but no other differences were noted possibly due to the smaller sample size.

Conclusion

The underestimation of sleep apnea using CMS criteria is consistent with prior literature; however, this is the first study to report the impact of the criteria in persons with moderate to severe TBI during a critical stage of neural recovery. Management of comorbidities in TBI has become an increasing focus for optimizing TBI outcomes. Given the chronic morbidity after moderate to severe TBI, the impact of CMS policy for OSA diagnosis for persons with chronic disability and young age are considerable.

Support

PCORI (CER-1511-33005), GDHS (W91YTZ-13-C-0015; HT0014-19-C-0004)) for DVBIC, NIDILRR (NSDC Grant # 90DPTB00070, #90DP0084, 90DPTB0013-01-00, 90DPTB0008, 90DPT80004-02).
0613 The Effects of Diabetes on Obstructive Sleep Apnea Severity and Progression: A Propensity Score Analysis
Authors: Li Q , Keenan B T , Punjabi N M , Maislin G , Kuna S T
Published: May 2020

Introduction

Obstructive sleep apnea (OSA) is associated with increased glucose intolerance and insulin resistance, and commonly coexists with type 2 diabetes mellitus (T2DM). Research suggests an independent association between these two conditions. However, more research into the role of T2DM in the development of OSA, or vice versa, is needed.

Methods

Leveraging data from 139 participants with T2DM from the Sleep AHEAD cohort and 5,085 participants without T2DM from the Sleep Heart Health Study (SHHS), we conducted two complementary propensity score (PS) subclassification analyses to estimate the effect of T2DM on the oxygen desaturation index (ODI), both at baseline and over 4-5 years of follow-up. PS models included age, sex, race, body mass index, neck circumference, waist circumference, total cholesterol, HDL cholesterol, triglycerides, Epworth Sleepiness Scale, and comorbid hypertension or cardiovascular disease. Models evaluating ODI progression also included baseline ODI.

Results

The PS subclassification analysis identified 109 participants with T2DM and 480 without T2DM, balanced with respect to baseline covariates, for evaluation of the effect of T2DM on baseline ODI. On average, those with T2DM had a 9 events/hour greater ODI compared to those without (24.3 [20.8, 27.9] vs. 15.3 [13.6, 16.9] events/hour; p<0.0001). Among patients with baseline ODI≥5, a second PS subclassification identified 99 with T2DM and 227 without for evaluating the effect of T2DM on ODI progression. No difference in change in ODI was observed between those with and without T2DM (mean [95% CI] difference -0.25 [-10.7, 10.2] events/hour; p=0.963).

Conclusion

Using two robust PS subclassification designs to minimize selection bias, we evaluated the effect of T2DM on baseline ODI and ODI progression in adults with OSA after 4-5 years. Those with T2DM had more severe baseline ODI, but there were no meaningful differences in ODI progression. Results further our understanding of the association between these coexisting conditions.

Support

NIH grant HL070301
0616 Validation of a Sleep Headband for Detecting Obstructive Sleep Apnea
Authors: Guillot A , Moutakanni T , Harris M , Arnal P J , Thorey V
Published: May 2020

Introduction

Polysomnography (PSG) is the gold-standard to diagnose obstructive sleep apnea (OSA). OSA severity diagnosis is defined by the apnea-hypopnea index (AHI) defined as the number of apnea and hypopnea events measured per hour of sleep. The Dreem2 headband (DH) is a self-administered, easy to use device that measure EEG, breathing frequency, heart rate and sound at-home. In our study, we assessed the performance of the DH to automatically detects OSA compared to 3 sleep’s experts scoring on PSG.

Methods

41 subjects (8 females, 42.6 ± 13.7 y.o.) having a suspicion of OSA performed a night at-home wearing both a PSG and the DH. Each PSG record was scored for apnea and hypopnea events by 3 independent trained sleep experts following AASM guidelines. The deep learning approach DOSED, was trained on the DH signals using the manual apnea scoring. 10-fold cross-validation was used to provide predictions for each of the 41 subjects with the DH.

Results

We observed an average AHI expert’s scoring of 13.6 ± 10.1 CI[10.5, 16.5] compared to 12.9 ± 10.3 CI[9.6, 15.8] for the DH. Both, the correlation between the 3 scorers (r= 0.88, p < 0.001) and the DH and the scorers (r=0.79, p< 0.001) were significant. The specificity and sensitivity to detect mild OSA (AHI ≤ 5) was 84.4 % and 96.4 % for the DH and 86.5 % and 86.0% for the scorers.

Conclusion

The results show that the DH using deep learning can detect OSA with an accuracy similar to the sleep experts. The use of DH paves the way for longitudinal monitoring of patients with a suspicion of OSA and its accessibility could lead to better screening of the general population.

Support

This Study has been supported by Dreem sas.
0660 The Association Between Sleep-Related Breathing Disorders and Free Flap Reconstruction Surgery in Patients With Oral and Oropharyngeal Cancers During 6-Month Follow-Up
Authors: Fu-Hsin L , Chan-Chi C , Yu-Cheng L , Wei-Shu L , Cheng-Yu L
Published: May 2020

Introduction

Little was known about the association between sleep-related breathing disorders (SRBDs) and oral and oropharynx cancers (OOCs). To clarify the impact of free flap reconstruction on SRBDs, we performed a pilot study to investigate the change of SRBDs severity in patients with OOC before and after flap reconstruction surgery.

Methods

This study recruited 15 patients who were newly diagnosed with OOCs and expected to receive free flap reconstruction surgery. For each participant, polysomnography tests were performed repeatedly at the time of pre-operative, post-operative 1-week, and post-operative 6-month periods.

Results

All the subjects were male. Median age was 56 years (range 37-68). Mean of body mass index (BMI) was 24.5 (SD 5.8). Pre-operative apnea-hypopnea index (AHI) was 21.1/hour (SD 20.1). During post-operative 1-week period, BMI was 24.1(SD 5.8) and AHI was 40.2/hour (SD 27.9). During post-operative 6-month period, BMI was 23.4 (SD 3.3) and AHI was 33.3/hour (SD 21.6). Comparison between pre-operative and post-operative 6-month periods, there was no significant difference in BMI, but AHI increased significantly (21.1/hour v.s. 33.3/hour, P = 0.01).

Conclusion

Our study showed that OOCs patients with free flap reconstruction surgery had significantly increased AHI level during post-operative 1-week period. The SRBDs severity became partial remission after 6 months. We recommend that the head and neck cancer team should pay attention to the SRBDs issues in OOCs patients with free flap reconstruction surgery.

Support
0681 Comparison Of Upper Airway Stimulation Outcomes Between Regions And Bmi Groups From The Adhere Registry
Authors: Walia H K , Mehra R , Kominsky A , Kent D , Pham H , Upender R , Manchanda S
Published: May 2020

Introduction

As factors influencing Upper Airway Stimulation (UAS) effectiveness in obstructive sleep apnea (OSA) patients are of interest, we compared changes in apnea hypopnea index (AHI) and Epworth Sleepiness Scale (ESS) based on region and baseline body mass index (BMI).

Methods

Patients (15≥AHI≤65) of the ADHERE registry with AHI at one-year were grouped by region (Europe (EU) vs United States (US)), and BMI (≤32kg/m2 vs 32-35kg/m2). T-tests and equivalence testing (if the former non-significant) was performed using two-one-sided t-tests. Equivalence margin for AHI was set between -5 and 5 and -2 and 2 for ESS.

Results

By December 2019, 553 of 1600 patients completed 1-year follow-up. Average age was 60±11, 75% male, BMI 29±4 kg/m2, ESS=11±6. Median AHI decreased from 33 to 10, median ESS decreased from 11 to 6. Response defined by 50% AHI reduction and <20 was 70%. Both regions had similar improvements in median AHI (EU: 33 to 10, US: 34 to 10, p < 0.001 vs baseline), median ESS (EU: 12 to 7; US: 11 to 6, p<0.001 vs baseline), and treatment response (EU: 71%, US: 68%). The mean AHI and ESS difference between regions met the equivalence margin. (AHI: mean difference: 0.34, CI:-1.78, 2.46, ESS: mean difference: 0.57, CI:-0.04, 1.19). Mean change in AHI at 1-year was equivalent in BMI groups (≤32 kg/m2 vs 32-35 kg/m2 respectively) median difference: -19.6 vs. -18.8; mean difference: -0.48, (CI:-3.95, 2.97) However, treatment response ratio was different; 73% vs. 60%, p=0.02, i.e. higher BMI patients were less likely to achieve AHI < 20. ESS scores were equivalent; median: 6 vs. 7; mean difference: -0.33, CI: [-1.16, 0.47].

Conclusion

UAS influence on OSA severity defined by AHI and sleepiness was similar irrespective of region and BMI category, however, treatment response defined by 50% AHI reduction and <20 was greater in those with lower BMI.

Support

The statistical support was provided by Inspire Medical System.
0687 Comparative Changes Of Patient Reported Outcomes In Positive Airway Pressure And Upper Airway Stimulation For Obstructive Sleep Apnea
Authors: Bhambra R , Pascoe M , Kominsky A , Mehra R , Aylor J , Wang L , Phillips K , Waters T , Walia H K
Published: May 2020

Introduction

Upper Airway Stimulation (UAS) is increasingly being used for obstructive sleep apnea (OSA) treatment, however, data comparing changes in patient reported outcomes (PROs) in response to positive airway pressure (PAP) versus UAS are limited. We hypothesize that there will be no difference in PROs between the two groups after treatment.

Methods

UAS and PAP groups were 1:3 matched on age, sex, Body Mass Index (BMI) and Apnea Hypopnea Index (AHI, category 15-30, >30). Linear mixed models assessed the difference of change in Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), Patient Health Questionnaire (PHQ9) and Insomnia Severity Index (ISI) measures on matched strata of UAS versus PAP groups with adjustment of baseline and matching factors. All analysis was performed in SAS software (version 9.4, Cary, NC).

Results

The analytic sample comprised 193 PAP patients and 69 UAS patients, with mean age=62.9+/-9.4 years, 27.5% female, mean BMI=29.1+/-3.2kg/m2, and median AHI 42.7, IQR: 31.5, 57.2. ESS in PAP (n=190) reduced by -2.63 (-3.38,-1.88) and in UAS (n=56) reduced by -2.22 (-3.34, -1.10), with a mean difference of 0.41 (-0.70, 1.52, p=.46). FOSQ in PAP (n=188) showed a change of 1.38 (0.99, 1.78) and in UAS (n=49) a change of 1.82 (1.17, 2.46), with a mean difference of 0.43 (-0.23, 1.09, p=.19). PHQ9 in PAP (n=185) showed a significant change of -2.24(-3.00, 1.47) and in UAS (n=45) a change of -3.75(-5.07,-2.42), with a mean difference of -1.51(-2.93,-0.088, p=.038). ISI in PAP (n=193) showed a significant change of -3.20(-4.39,-2.02) and in UAS (n=47) a change of -4.83(-6.77,-2.90), with a mean difference of -1.63(-3.62, 0.37, p=.11).

Conclusion

Similar improvements in PROs were observed in both UAS and PAP patient groups, however UAS appeared to confer greater benefit in depressive symptoms relative to PAP. Randomized clinical trials should be designed to confirm these findings.

Support

N/A
0688 Evaluation Of A Novel Nasal Airway Stent For Snoring And OSA Treatment By Prospective Japanese Patients
Authors: Wang W , Ding F , Satoh M , Kushida C
Published: May 2020

Introduction

This cross-sectional study evaluated a novel nasal airway stent (NAS) in the form of a single-use, disposable device (naśtent® classic, Seven Dreamers Laboratories, Inc., Tokyo, Japan), which represents a significant advancement in NAS technology for the treatment of OSA.

Methods

1353 individuals whom were interested in NAS treatment for their snoring and/or OSA were enrolled in this study conducted in different districts in Tokyo, Japan from 8/21/2015 to 3/7/2016. A total of 1335 participants with complete data were included in the final dataset. Collected data included demographic features, self-reported sleep and OSA characteristics, anatomic traits, Epworth Sleepiness Scale (ESS) scores, and NAS tolerance.

Results

The majority of the participants were middle-aged men (91.5% male, 45±10.8 years) with normal BMI (24.5±5.7). Self-reported sleep was 9-11 hours (0.1%), 7-9 hours (8.2%), 5-7 hours (66.7%), 3-5 hours (22%), 1-3 hours (1.2%), and unreported (1.9%). Their mean Epworth Sleepiness Scale score was 9±5.56, and their peak Mallampati and tonsillar grading scores were 2/4 and 3/5, respectively. Of the participants, 87.4% were aware of possible OSA either by snoring or by prior diagnosis of OSA, and their reasons for desiring use of NAS therapy presented in a similar ratio. Over 80% of the participants had never been treated for their diagnosis of OSA; for those with current or prior treatment for their OSA, 62.9% reported PAP as their primary therapy, followed by oral appliances (25.7%), surgery (0.5%), and other therapies (10.8%). On a scale of 1 to 5 where 5 indicated good tolerance to the NAS, the mean scores were 4±1.3 for easy of insertion and 4±1.2 for convenience of use.

Conclusion

This large, cross-sectional study indicated that the majority of individuals seeking a novel NAS treatment for their snoring and/or OSA in Tokyo, Japan were middle-aged men with 5-7 hours of self-reported sleep whom had some daytime sleepiness, displayed signs of mild anatomic upper airway narrowing, had not been treated for their OSA, and whom felt that the NAS was easy and convenient to use.

Support

Seven Dreamers Laboratories, Inc. and WSS ISRTP
0701 Positive Airway Pressure Therapy To Treat Sleep Disordered Breathing Impacts Number Of Hospitalizations In Patients With Heart Failure
Authors: Patel S I , Vasquez M , Huang F , Combs D , Parthasarathy S
Published: May 2020

Introduction

Some studies have shown a benefit while others have shown possible harm in patient outcomes when using positive airway pressure therapy (PAP) for treating sleep disordered breathing (SDB) in patients with heart failure (HF). The goal of this study was to evaluate the number of HF-related and all-cause related hospitalizations in patients with HF and SDB on various forms of PAP therapy versus those on no PAP therapy.

Methods

Administrative claims data from the Truven Health MarketScan Database from 1/1/2005- 10/31/2015 were analyzed. Those included were at least 21 years old, were continuously enrolled for 12 months before and 6 months after their index date (date of PAP prescription), had at least two distinct HF-related claims and were prescribed PAP therapy (n=1,324,414). To model the relationship between each device and hospitalization risk, and to account for the longitudinal and correlated nature of these binary outcome data, generalized estimating equations with binomial family, logit link, and unstructured correlation structure were used.

Results

There were a total of 12,538 patients on Bilevel-PAP, 2,700 patients on bilevel-PAP with backup rate, and 57,405 patients on CPAP, and 73,353 patients with HF and comorbid sleep apnea who were not on any treatment. The reduction in HF-related hospitalization for patients with HF and comorbid SDB treated with bilevel-PAP therapy (0.28; 95% CI 0.26, 0.31) was greater than that in patients receiving CPAP (OR 0.46 95% CI 0.43, 0.49), bilevel PAP with back-up rate (0.39; 95% CI 0.32, 0.49), or no PAP treatment (OR 0.54; 95%CI 0.50, 0.57)(P<0.01). Similar trend was observed for all-cause related hospitalizations. All results were adjusted for propensity score and other relevant confounders.

Conclusion

In claims-based analysis of patients with HF and comorbid SDB, bilevel PAP treatment was associated with reduced hospitalizations when compared to CPAP therapy or no PAP treatment.

Support

Phillips Respironics
0712 CPAP Compliance: Roles Of Depressive Symptoms, Polysomnographic And Self-report Sleep Measures
Authors: Dubrovsky B , Inamac A , Gikashvili L , Weingarten J , Cunningham J
Published: May 2020

Introduction

OSA poses major health risks; however, CPAP compliance is often suboptimal. Comorbid insomnia and depression contributed to poor CPAP compliance in different studies. Presently, PSG variables, self-report measures of insomnia, sleep quality and depression were tested simultaneously as predictors of compliance in new CPAP users who at 180 days of therapy had any non-zero use of CPAP.

Methods

PSG-diagnosed 47 patients (18-79 y.o., 24 women) were titrated in the lab and initiated on CPAP. Compliance was assessed during days 1-30 and 151-180. For each period, percentage of days with >4hrs of CPAP use (%>4h-days30, %>4h-days180) and the average hours-per-day use (Tav30, Tav180) were measured. After regressing each compliance variable on age, sex and BMI, one at a time were tested: PSG variables from the diagnostic and titration studies, subjective reactions to CPAP after titration (sleep better vs. same/worse than usual; will vs. won’t use CPAP at home), pre-treatment ISI, PSQI, ESS, and Center for Epidemiologic Studies Depression Scale-Revised (CESDR).

Results

AHI ranged 6/hr-101/hr (M=24.2±19.5); %>4h-days30, 0-100% (M=68%±32%); Tav30, 0.0-9.8 hours (M=5.2±2.5); %>4h-days180, 0-100% (M=64%±34%); Tav180, 0.2-10.5 hours (M=4.7±2.8). PSG variables from both diagnostic and titration studies, reactions to CPAP, ESS and CESDR were not significant predictors of compliance (all p>0.1). ISI was marginally inversely related to %>4h-days30 (p=0.087) and Tav30 (p=0.075). Higher pre-treatment PSQI was related to lower %>4h-days30 (p=0.003, R2=19%) and Tav30 (p=0.011, R2=15%). Entered alone, PSQI was related to %>4h-days180 (p=0.042) and Tav180 (p=0.043); however, when the 1-30-day compliance was accounted for, PSQI no longer related to the 151-180-day compliance. The 1-30-day compliance strongly predicted respective 151-180-day measures (%>4h-days, p<0.001, R2=55%; Tav, p<0.001, R2=68%).

Conclusion

In this limited sample of naive CPAP users, higher pre-treatment sleep disturbance reported on PSQI was a useful predictor of lower 1-30-day CPAP compliance. Neither depressive symptoms nor PSG variables from diagnostic and titration studies predicted compliance. As the initial 30-day compliance is the best predictor of later CPAP use, early interventions are crucial.

Support

none
0729 Sleep Apnea Diagnosis And Severity And Their Impact On Cognition After TBI: A VA TBI Model Systems Study
Authors: Silva M A , Brennan E M , Noyes E , Royer A , Nakase-Richardson R
Published: May 2020

Introduction

For persons with moderate-to-severe traumatic brain injury (TBI), chronic cognitive impairment contributes to long term disability. Health comorbidities may contribute to the neurologic burden in TBI. Indeed, obstructive sleep apnea (OSA) is associated with neuropathological and cognitive changes. The objective of this study was to examine the relationship between OSA and cognition after TBI.

Methods

Participants were prior inpatient rehabilitation patients drawn from the Tampa VA TBI Model Systems longitudinal study. Post-discharge interviews occurred 2 to 6 years post-TBI. Participants reported whether they were diagnosed with OSA and completed the Brief Test of Adult Cognition by Telephone (BTACT) which measures recall, working memory, processing speed, fluency, and reasoning. Participants with polysomnography (PSG) were separately analyzed to examine the impact of sleep apnea severity (i.e., Apnea-Hypopnea Index [AHI]) on cognition.

Results

Participants (N=104) were mostly male (95.2%), age M=37.7 (SD=12.5), Education M=13.6 years (SD=2.1), and 45.2% were diagnosed with OSA. Participants with and without OSA did not differ by age, education, gender, or time since injury at time of BTACT (ps > .05). ANCOVAs were conducted examining OSA diagnosis on BTACT subscale scores, covarying TBI severity level, but results did not reach statistical significance (ps > .05). A subset of participants with OSA had PSG (n=27), AHI score quartiles = 6.7/10.4/21.6. Higher AHI was associated with poorer reasoning (Spearman ρ = -0.45, p = .019). Nonsignificant results were found for word recall (Spearman ρ = -0.35, p = .074) and processing speed (Spearman ρ = -0.36, p = .069).

Conclusion

Severity of sleep apnea may influence aspects of cognition among persons with TBI, although these results are preliminary and need replication with a larger and more representative sample.

Support

This work was supported by the Veterans Health Administration Central Office VA TBI Model Systems Program of Research and subcontract from General Dynamics Information Technology [W91YTZ-13-C-0015, HT0014-19-C-0004] from the Defense and Veterans Brain Injury Center (DVBIC); and from the United States Department of Veterans Affairs [W81XWH-13-2-0095]; and from the United States Department of Defense Congressionally Directed Medical Research Programs; and from the Patient Centered Outcomes Research Institute (PCORI) [CER-1511-33005].
0734 Does Noise Masking Improve Sleep Consolidation In Patients Weaning From Prolonged Mechanical Ventilation?
Authors: Shaikh H , Chung P , Jubran A , Tobin M , Laghi F
Published: May 2020

Introduction

Sound masking is a noise reduction strategy that adds a mixed-frequency blend of ambient sound to the environment and may improve sleep. Critically ill patients often cite noise as one of the main factors preventing sleep while they are cared for in an intensive care unit (ICU). The effect of sound masking on sleep in patients weaning from prolonged mechanical ventilation is unknown.

Methods

12-hour overnight polysomnography was obtained in eight patients undergoing weaning from prolonged mechanical ventilation. None had hearing impairment, delirium, sedation or agitation. In random order, patients were exposed to sound masking half of the recording time. Noise events were defined a 10dB increase from baseline or any sound peak over 75dB. Arousals or awakenings were attributed to noise if they occurred within 5 seconds of the noise event.

Results

Environmental sound was 61.7± 0.9 dB (mean±SE) during sound masking and 55.9±1.4 dB during no sound masking. During sound masking, there were fewer sound events per hour of sleep when compared to no sound masking (4.1/hr vs 9.3/hr p=0.03). The percentage of sound events leading to a subsequent arousal or awakening with sound masking was less than during no sound masking:11% vs 22% (p=0.04). Arousal index and fragmentation index (arousal and awakenings/hr of sleep) were similar between the two conditions. In a post-study survey, five patients reported improved sleep quality with sound masking while the remaining three reported no difference.

Conclusion

Sound masking decreases sound-induced arousal from sleep in patients being weaned from prolonged mechanical ventilation.

Support

Veterans Administration Research Service
0739 Efficacy and Safety of AXS-12 in the Treatment of Narcolepsy: Results from a Phase 2, Double-Blind, Placebo-Controlled, Crossover Trial
Authors: O’Gorman C , Jones A , Thorpy M J , Tabuteau H
Published: May 2020

Introduction

Narcolepsy is a chronic, debilitating, neurological disease characterized by excessive daytime sleepiness (EDS), cataplexy, and sleep-wake dysregulation. Existing treatments are limited, provide variable efficacy, and have significant tolerability issues. AXS-12 (reboxetine) is a potent, and highly selective norepinephrine reuptake inhibitor with potential for therapeutic differentiation in narcolepsy.

Methods

The CONCERT study was a Phase 2, double-blind, randomized, placebo-controlled, crossover trial of AXS-12 in narcolepsy subjects exhibiting moderate and severe symptoms of cataplexy and EDS. Subjects were randomized (1:1) to treatment with AXS-12 followed by placebo, or placebo followed by AXS-12. AXS-12 dosing was 8mg/day for week 1, escalated to 10mg/day for week 2. Crossover occurred after a one-week down-titration/washout. The primary endpoint was the change in weekly cataplexy attacks from baseline, averaged over the 2-week treatment period for overall treatment effect. Secondary endpoints included improvements in EDS, cognitive function, sleep quality and sleep-related symptoms.

Results

Twenty-one subjects were randomized. The baseline mean weekly number of cataplexy attacks was 30.0 and mean ESS score was 18.1, reflecting moderate and severe illness on both core symptoms. AXS-12 met the prespecified primary endpoint, demonstrating a statistically significantly greater reduction in the mean number of weekly cataplexy attacks (-13.0 with AXS-12 vs -0.3 with placebo; p<0.001) over 2 weeks of treatment. Statistically significant reductions in EDS were observed for AXS-12 compared to placebo, assessed by changes in the Epworth Sleepiness Scale (-6.0 vs -3.1; p=0.003), number of weekly inadvertent naps (-5.88 vs -0.98; p<0.001). AXS-12 was associated with improved cognitive function (p<0.002) and sleep quality (p<0.007), and reduced night awakenings (p<0.05). Rapidity of effect was observed with significant symptomatic improvements occurring as early as week 1 starting at the lower 8mg dose. AXS-12 was safe and well-tolerated with no serious adverse events or discontinuations due to adverse events.

Conclusion

AXS-12 is a novel approach for the treatment of narcolepsy with the potential for comprehensive clinical symptom management compared to current treatments. In this Phase 2 study, AXS-12 resulted in statistically significant improvements in cataplexy, excessive sleepiness, cognitive function and night awakenings in patients with narcolepsy with a favorable safety profile.

Support

Axsome Therapeutics.